STOCK TITAN

VectivBio Holding AG - VECT STOCK NEWS

Welcome to our dedicated news page for VectivBio Holding (Ticker: VECT), a resource for investors and traders seeking the latest updates and insights on VectivBio Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VectivBio Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VectivBio Holding's position in the market.

Rhea-AI Summary
Alentis Therapeutics has appointed Dr. Luca Santarelli as the Chair of its Board of Directors. Santarelli, a serial biotech entrepreneur, brings extensive experience in academic and pharmaceutical R&D. Alentis aims to become a global leader in developing medicines for cancer and fibrosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
management
-
Rhea-AI Summary
Ironwood Pharmaceuticals and VectivBio Holding AG have successfully completed the tender offer for the outstanding ordinary shares of VectivBio. The tender offer was priced at $17.00 per share in cash, and approximately 97.60 percent of the outstanding shares were tendered. Ironwood intends to delist VectivBio's shares from Nasdaq and proceed with a squeeze-out merger under Swiss law.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
Rhea-AI Summary
Ironwood Pharmaceuticals and VectivBio announce expiration of waiting period for acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
-
-
Rhea-AI Summary
VectivBio Holding AG has published the invitation to its 2023 Annual General Meeting, which will be held on June 1, 2023. Shareholders with voting rights as of May 2, 2023, will be able to participate. Further details can be found at www.edocumentview.com/VECT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.39%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
VectivBio Holding AG

Nasdaq:VECT

VECT Rankings

VECT Stock Data

1.06B
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link

About VECT

vectivbio ag is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. vectivbio was formed in 2019 as a spinout from therachon, a biotechnology company acquired by pfizer, inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. the company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in r&d, commercialization and business development for innovative products targeting orphan conditions with major unmet medical need. the company is drawing on the expertise of its founders as it continues to build a portfolio of rare disease medicines while advancing its lead program for short bowel syndrome.